NADPH Oxidase Inhibitors: New Antihypertensive Agents?
- 1 July 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 50 (1) , 9-16
Abstract
NADPH oxidases have recently been shown to contribute to the pathogenesis of hypertension. The development of specific inhibitors of these enzymes has focused attention on their potential therapeutic use in hypertensive disease. Two of the most specific inhibitors, gp91ds-tat and apocynin, have been shown to decrease blood pressure in animal models of hypertension. Other inhibitors, including diphenylene iodonium, aminoethyl benzenesulfono fluoride, S17834, PR39, protein kinase C inhibitors, and VAS2870, have shown promise in vitro, but their in vivo specificity, pharmacokinetics, and effectiveness in hypertension remains to be determined. Of importance, the currently available antihypertensive agents angiotensin-converting enzyme inhibitors and angiotensin receptor blockers also effectively inhibit NADPH oxidase activation. Similarly, the cholesterol-lowering agents, statins, have been shown to attenuate NADPH oxidase activation. Although, antioxidants act to scavenge the reactive oxygen species produced by these enzymes, their effectiveness is limited. Targeting NADPH homologues may have a distinct advantage over current therapies because it would specifically prevent the pathophysiological formation of reactive oxygen species that contributes to hypertension.Keywords
This publication has 102 references indexed in Scilit:
- Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation☆Cardiovascular Research, 2006
- Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cellsBiochemical and Biophysical Research Communications, 2006
- NADPH Oxidase in the Renal Medulla Causes Oxidative Stress and Contributes to Salt-Sensitive Hypertension in Dahl S RatsHypertension, 2006
- Vascular Hypertrophy in Angiotensin II–Induced Hypertension Is Mediated by Vascular Smooth Muscle Cell–Derived H 2 O 2Hypertension, 2005
- Angiotensin II-induced hypertrophy is potentiated in mice overexpressing p22phox in vascular smooth muscleAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- gp91phox-Containing NADPH Oxidase Mediates Endothelial Dysfunction in Renovascular HypertensionCirculation, 2004
- Reactive Oxygen Species in the Cerebral CirculationDrugs, 2004
- Endothelin-1 Increases Vascular Superoxide via Endothelin A –NADPH Oxidase Pathway in Low-Renin HypertensionCirculation, 2003
- Endothelial Function in HypertensionHypertension, 1999
- Role of superoxide anions in the mediation of endothelium-dependent contractions.Hypertension, 1994